Phillip Paul Minar

19PUBLICATIONS
73CO-AUTHORS
Rheumatology and arthritisPharmacogenomicsInfant and child healthPharmaceutical delivery technologiesChild and adolescent development
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 12, 2026
Evaluation of pharmacokinetic metrics and pharmacodynamic biomarkers associated with endoscopic healing in pediatric Crohn's disease patients treated with anti-tumor necrosis factor biologics.

|Jul 26, 2026
Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn's Disease.

|Jun 30, 2026
The Safety and Effectiveness of Early Anti-tumor-necrosis-factor Therapy for Penetrating Crohn's Disease Complications in Children.

|Nov 05, 2025
Model-Informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's Disease.

Kei Irie, Phillip Minar, Jack Reifenberg

|May 02, 2025
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease.

Jeremy Adler, Joseph A Galanko, Rana Ammoury

|Feb 22, 2025
Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease.

Abigail Samuels, Kei Irie, Tomoyuki Mizuno

Pageof 4

Frequent Collaborators

4 joint publications

Tomoyuki Mizuno

3 joint publications

Ruben J Colman

3 joint publications

Jeffrey S Hyams

3 joint publications

Alexander A Vinks